ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO233

Correlation Between Albuminuria and Echocardiographic (Echo) Abnormalities in Individuals With Type 2 Diabetes (T2D): Insights From the Take Care of Me (TCoM) Program

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical


  • Vasnawala, Hardik, AstraZeneca, India, Bangalore, India
  • Goncalves, Susana, AstraZeneca, Argentina, Buenos Aires, Argentina
  • Khunti, Kamlesh, University of Leicester, Leicester, United Kingdom
  • Fenici, Peter, AstraZeneca, S.p.A, Milan, Italy
  • L Heerspink, Hiddo Jan, Department of Clinical Pharmacology of the University Medical Center Groningen, Groningen, Netherlands
  • Joshi, Shashank R., Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India
  • Kosiborod, Mikhail, Saint Luke’s MidAmerica Heart Institute, University of Missouri-Kansas City, Kansas city, Missouri, United States
  • Lam, Carolyn, National Heart Center, Singapore, Singapore
  • Nicolucci, Antonio, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy
  • Ramirez, Larisa, AstraZeneca, Latam, San Jose, Costa Rica
  • Silva, Alejandra, AstraZeneca, Latam, San Jose, Costa Rica
  • Surmont, Filip, AstraZeneca, China, Shanghai, China
  • Vazquez Mendez, Estefania, AstraZeneca, Mexico, Guadalajara, Mexico

Cardiovascular (CV) and renal diseases are the most common and morbid complications of T2D. The TCoM program, a subset of the iCaReMe global, cloud-based registry (NCT03549754), assessed the correlation between albuminuria and echo abnormalities in individuals with T2D.


Cross-sectional data of adults (>18 years) with T2D and no known cardiorenal complications (CRCs) at index visit, enrolled from routine clinical practice from Mexico, Argentina, Egypt, India, Malaysia, and the Philippines, were collected between December 2020 and December 2021. Correlation was assessed using Cramer’s V-value and Fisher’s exact/chi-square test.


Of 12320 enrolled individuals (mean±SD age, 54.6±11.3 yrs; 59.3% women), 4853 had high/very high CV risk. Of these, 1506 (31%) had echo data; 450 (29.9%) of them had abnormal echo: 17.3% left ventricular hypertrophy, 16.8% left atrial enlargement, 4.3% diastolic dysfunction, 4.1% pulmonary hypertension, and 3.8% valvular disease. Echo abnormalities were significantly higher in individuals with albuminuria A2/A3 than those with A1 (33.5% vs 24.7%, p<0.05, v=0.094; Table). Significant correlation (p<0.05) was found between albuminuria and T2D duration (v=0.117), HbA1c (v=0.168), and CV risk (v=0.857).


Among individuals with T2D and high/very high CV risk from low-middle income countries, there is a significant correlation between albuminuria (stages A2/A3) and abnormal echo. Early detection of albuminuria through screening may be the key to effective management of CRCs in these individuals.

Factors associated with echocardiographic abnormalities and albuminuria


  • Commercial Support